STOCK TITAN

[Form 4] Robinhood Markets, Inc. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

Form 4 overview: On 07/11/2025, DENTSPLY SIRONA Inc. (XRAY) director Janet S. Vergis reported the automatic credit of 139.41 restricted stock units (RSUs) as dividend equivalents. The RSUs were acquired at $0 cost and carry the same vesting schedule as the underlying awards, converting to common stock on a 1-for-1 basis. Following the transaction, Vergis now beneficially owns 44,120.718 XRAY shares, all held directly. No shares were sold, and no derivative transactions were reported.

The filing represents a routine administrative adjustment rather than an open-market purchase, providing minimal insight into insider sentiment or near-term fundamentals.

Panoramica del Modulo 4: Il 07/11/2025, la direttrice di DENTSPLY SIRONA Inc. (XRAY), Janet S. Vergis, ha riportato l'accredito automatico di 139,41 unità azionarie vincolate (RSU) come equivalenti dividendi. Le RSU sono state acquisite a costo zero e seguono lo stesso calendario di maturazione delle azioni sottostanti, convertendosi in azioni ordinarie con un rapporto di 1:1. Dopo la transazione, Vergis detiene beneficiariamente 44.120,718 azioni XRAY, tutte possedute direttamente. Non sono state vendute azioni né segnalate operazioni su derivati.

La comunicazione rappresenta un aggiustamento amministrativo di routine piuttosto che un acquisto sul mercato aperto, offrendo scarsi spunti sul sentiment interno o sui fondamentali a breve termine.

Resumen del Formulario 4: El 07/11/2025, la directora de DENTSPLY SIRONA Inc. (XRAY), Janet S. Vergis, informó el crédito automático de 139,41 unidades restringidas de acciones (RSU) como equivalentes a dividendos. Las RSU se adquirieron a costo cero y tienen el mismo calendario de adjudicación que las acciones subyacentes, convirtiéndose en acciones comunes en una proporción de 1 a 1. Tras la transacción, Vergis posee beneficiariamente 44.120,718 acciones de XRAY, todas en propiedad directa. No se vendieron acciones ni se reportaron transacciones con derivados.

La presentación representa un ajuste administrativo rutinario más que una compra en el mercado abierto, proporcionando poca información sobre el sentimiento interno o los fundamentos a corto plazo.

Form 4 개요: 2025년 11월 7일, DENTSPLY SIRONA Inc.(XRAY) 이사 Janet S. Vergis는 배당금과 동일한 139.41 제한 주식 단위(RSU)가 자동으로 적립되었음을 보고했습니다. RSU는 0달러 비용으로 취득되었으며, 기초 수상과 동일한 베스팅 일정에 따라 1대1 비율로 보통주로 전환됩니다. 거래 후 Vergis는 직접 보유한 44,120.718 XRAY 주식을 실질적으로 소유하게 되었습니다. 주식 매도나 파생상품 거래는 보고되지 않았습니다.

이번 신고는 공개 시장 매수가 아닌 일상적인 행정 조정으로, 내부자 심리나 단기 펀더멘털에 대한 통찰은 제한적입니다.

Présentation du formulaire 4 : Le 07/11/2025, Janet S. Vergis, administratrice de DENTSPLY SIRONA Inc. (XRAY), a déclaré le crédit automatique de 139,41 unités d'actions restreintes (RSU) en tant qu'équivalents dividendes. Les RSU ont été acquises à coût nul et suivent le même calendrier d'acquisition que les actions sous-jacentes, se convertissant en actions ordinaires au ratio de 1 pour 1. Suite à la transaction, Vergis détient désormais bénéficiairement 44 120,718 actions XRAY, toutes détenues directement. Aucune action n'a été vendue et aucune transaction sur dérivés n'a été déclarée.

Le dépôt représente un ajustement administratif de routine plutôt qu'un achat sur le marché ouvert, fournissant peu d'indications sur le sentiment des initiés ou les fondamentaux à court terme.

Überblick über Formular 4: Am 07.11.2025 meldete Janet S. Vergis, Direktorin von DENTSPLY SIRONA Inc. (XRAY), die automatische Gutschrift von 139,41 Restricted Stock Units (RSUs) als Dividendenäquivalente. Die RSUs wurden zu Nullkosten erworben und unterliegen dem gleichen Vesting-Zeitplan wie die zugrunde liegenden Awards, mit einer Umwandlung in Stammaktien im Verhältnis 1:1. Nach der Transaktion besitzt Vergis nun wirtschaftlich 44.120,718 XRAY-Aktien, alle direkt gehalten. Es wurden keine Aktien verkauft und keine Derivatgeschäfte gemeldet.

Die Meldung stellt eine routinemäßige administrative Anpassung dar und keinen Kauf am offenen Markt, weshalb sie nur begrenzte Einblicke in die Insider-Stimmung oder kurzfristige Fundamentaldaten bietet.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine RSU dividend credit; immaterial to valuation or insider sentiment.

The 139.41 RSUs increase the director’s stake by roughly 0.3%, a de minimis change given her 44 k-share position. Because the award stems from dividend equivalents rather than discretionary buying, it does not signal conviction on future price performance. With no cash consideration or change in vesting terms, the event is neutral for shareholders and has no direct impact on earnings, liquidity, or share count.

TL;DR: Standard equity accrual aligns director compensation; neutral impact.

Dividend-settled RSUs are commonplace in equity incentive plans, maintaining economic parity between RSU holders and common shareholders. The disclosure confirms proper Section 16 compliance and continued alignment of director incentives with shareholder value. There are no governance red flags, and the minor share increase does not affect board independence or control.

Panoramica del Modulo 4: Il 07/11/2025, la direttrice di DENTSPLY SIRONA Inc. (XRAY), Janet S. Vergis, ha riportato l'accredito automatico di 139,41 unità azionarie vincolate (RSU) come equivalenti dividendi. Le RSU sono state acquisite a costo zero e seguono lo stesso calendario di maturazione delle azioni sottostanti, convertendosi in azioni ordinarie con un rapporto di 1:1. Dopo la transazione, Vergis detiene beneficiariamente 44.120,718 azioni XRAY, tutte possedute direttamente. Non sono state vendute azioni né segnalate operazioni su derivati.

La comunicazione rappresenta un aggiustamento amministrativo di routine piuttosto che un acquisto sul mercato aperto, offrendo scarsi spunti sul sentiment interno o sui fondamentali a breve termine.

Resumen del Formulario 4: El 07/11/2025, la directora de DENTSPLY SIRONA Inc. (XRAY), Janet S. Vergis, informó el crédito automático de 139,41 unidades restringidas de acciones (RSU) como equivalentes a dividendos. Las RSU se adquirieron a costo cero y tienen el mismo calendario de adjudicación que las acciones subyacentes, convirtiéndose en acciones comunes en una proporción de 1 a 1. Tras la transacción, Vergis posee beneficiariamente 44.120,718 acciones de XRAY, todas en propiedad directa. No se vendieron acciones ni se reportaron transacciones con derivados.

La presentación representa un ajuste administrativo rutinario más que una compra en el mercado abierto, proporcionando poca información sobre el sentimiento interno o los fundamentos a corto plazo.

Form 4 개요: 2025년 11월 7일, DENTSPLY SIRONA Inc.(XRAY) 이사 Janet S. Vergis는 배당금과 동일한 139.41 제한 주식 단위(RSU)가 자동으로 적립되었음을 보고했습니다. RSU는 0달러 비용으로 취득되었으며, 기초 수상과 동일한 베스팅 일정에 따라 1대1 비율로 보통주로 전환됩니다. 거래 후 Vergis는 직접 보유한 44,120.718 XRAY 주식을 실질적으로 소유하게 되었습니다. 주식 매도나 파생상품 거래는 보고되지 않았습니다.

이번 신고는 공개 시장 매수가 아닌 일상적인 행정 조정으로, 내부자 심리나 단기 펀더멘털에 대한 통찰은 제한적입니다.

Présentation du formulaire 4 : Le 07/11/2025, Janet S. Vergis, administratrice de DENTSPLY SIRONA Inc. (XRAY), a déclaré le crédit automatique de 139,41 unités d'actions restreintes (RSU) en tant qu'équivalents dividendes. Les RSU ont été acquises à coût nul et suivent le même calendrier d'acquisition que les actions sous-jacentes, se convertissant en actions ordinaires au ratio de 1 pour 1. Suite à la transaction, Vergis détient désormais bénéficiairement 44 120,718 actions XRAY, toutes détenues directement. Aucune action n'a été vendue et aucune transaction sur dérivés n'a été déclarée.

Le dépôt représente un ajustement administratif de routine plutôt qu'un achat sur le marché ouvert, fournissant peu d'indications sur le sentiment des initiés ou les fondamentaux à court terme.

Überblick über Formular 4: Am 07.11.2025 meldete Janet S. Vergis, Direktorin von DENTSPLY SIRONA Inc. (XRAY), die automatische Gutschrift von 139,41 Restricted Stock Units (RSUs) als Dividendenäquivalente. Die RSUs wurden zu Nullkosten erworben und unterliegen dem gleichen Vesting-Zeitplan wie die zugrunde liegenden Awards, mit einer Umwandlung in Stammaktien im Verhältnis 1:1. Nach der Transaktion besitzt Vergis nun wirtschaftlich 44.120,718 XRAY-Aktien, alle direkt gehalten. Es wurden keine Aktien verkauft und keine Derivatgeschäfte gemeldet.

Die Meldung stellt eine routinemäßige administrative Anpassung dar und keinen Kauf am offenen Markt, weshalb sie nur begrenzte Einblicke in die Insider-Stimmung oder kurzfristige Fundamentaldaten bietet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Tenev Vladimir

(Last) (First) (Middle)
C/O ROBINHOOD MARKETS, INC.
85 WILLOW ROAD

(Street)
MENLO PARK CA 94025

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Robinhood Markets, Inc. [ HOOD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 07/11/2025 C 114,515 A (1) 114,515 D
Class A Common Stock 07/11/2025 S(2) 340 D $101.5 114,175 D
Class A Common Stock 07/14/2025 S(2) 114,175 D $101.6497(3) 0 D
Class A Common Stock 6,907 I By Living Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock (1) 07/11/2025 C 114,515 (1) (1) Class A Common Stock 114,515 $0 47,252,845 D
Explanation of Responses:
1. As part of the transactions effected on July 11, 2025 and July 14, 2025 pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on August 19, 2024 ("Tenev 10b5-1 plan"), the Reporting Person sold 114,515 shares of his Class B Common Stock, resulting in an automatic conversion of the shares into Class A Common Stock upon execution of the sale.
2. This transaction was effected pursuant to the Tenev 10b5-1 plan.
3. This transaction was executed in multiple trades during the day at prices ranging from $101.50 to $101.84. The weighted-average price is reported above. The Reporting Person hereby undertakes to provide to the SEC staff, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares and prices at which the trades were made.
Remarks:
/s/ Matthew Yorkavich, attorney-in-fact for Vladimir Tenev 07/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many XRAY shares did Janet S. Vergis acquire on 11 July 2025?

139.41 restricted stock units were credited as dividend equivalents.

What is Vergis’s total beneficial ownership after the transaction?

She now directly holds 44,120.718 shares of DENTSPLY SIRONA common stock.

Was the acquisition an open-market purchase?

No. It was an automatic dividend-equivalent RSU credit at $0 cost, not an open-market buy.

What is the conversion ratio for the reported RSUs?

Each RSU converts to one share of common stock (1:1) upon vesting.

Does this filing indicate bullish insider sentiment at XRAY?

The filing is routine and does not reflect discretionary buying; therefore, it is considered sentiment-neutral.
Robinhood Markets, Inc.

NASDAQ:HOOD

HOOD Rankings

HOOD Latest News

HOOD Latest SEC Filings

HOOD Stock Data

83.43B
759.53M
1.21%
73.56%
2.7%
Capital Markets
Security Brokers, Dealers & Flotation Companies
Link
United States
MENLO PARK